Presence of Mood and/or Anxiety Disorders Does Not Affect Success of Weight Management Therapies in Metabolic Dysfunction-Associated Steatotic Liver Disease
Digestive Diseases and Sciences · 2025
DOI: 10.1007/s10620-024-08724-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive Diseases and Sciences, 2025. Verfasst von Bryan Bollinger und 4 weiteren Autor:innen. Beteiligte Einrichtung: Yale University School of Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Anxiety Disorders, Mood Disorders, Weight Loss, Fatty Liver. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) and resultant steatohepatitis (MASH) have been linked to psychiatric comorbidities. The treatment of MASLD/MASH primarily relies upon weight loss, where achieving a 7% total body weight loss is recommended to improve steatohepatitis. We aimed to determine whether achieving a 7% total body weight loss (TBWL) in MASLD/MASH patients was significantly different in the presence of a mood and/or anxiety disorder in an interdisciplinary clinic that integrates weight management and hepatology care. METHODS: We conducted a single center retrospective cohort study of MASLD/MASH patients segregated into those with an ICD-10 diagnosis of a mood and/or anxiety disorder to those without. The primary outcome was reaching a 7% TBWL at 12 months with univariable and multivariable logistic regression models used to identify treatments predicting a 7% TBWL. Secondary outcomes were noninvasive assessment of steatohepatitis improvement, including change in ALT and FIB-4 scores. RESULTS: Of 567 patients with MASLD/MASH, 366 (64.6%) had a mood and/or anxiety disorder. The presence of psychiatric disease was not a significant predictor of weight loss or any secondary outcome measures at 12 months. Significant predictors of achieving 7% TBWL at 12 months among all patients with MASLD/MASH included semaglutide, phentermine-topiramate, and bariatric surgery. Significant predictors of achieving 7% TBWL at 12 months in patients with MASLD/MASH and a psychiatric comorbidity included semaglutide, topiramate, phentermine-topiramate, and bariatric surgery. Both groups experienced similar improvements in hepatic outcomes. CONCLUSIONS: Our findings suggest that obesity management in patients with MASLD/MASH performs similarly in the presence of comorbid mood and/or anxiety disorders. Topiramate and phentermine may be particularly effective in this patient population, yet are underutilized in routine hepatology practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Yale University School of Medicine, New Haven, CT, USA.
- Yale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT, USA.
- Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, 300 Cedar St., TAC S241, New Haven, CT, 06519, USA.
- Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, 300 Cedar St., TAC S241, New Haven, CT, 06519, USA. Vikas.Gupta@yale.edu.
Zitieren
APA
Bollinger, B., Cotter, R., Deng, Y., Ilagan-Ying, Y., & Gupta, V. (2025). Presence of Mood and/or Anxiety Disorders Does Not Affect Success of Weight Management Therapies in Metabolic Dysfunction-Associated Steatotic Liver Disease. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-024-08724-y
Vancouver
Bollinger B, Cotter R, Deng Y, Ilagan-Ying Y, Gupta V. Presence of Mood and/or Anxiety Disorders Does Not Affect Success of Weight Management Therapies in Metabolic Dysfunction-Associated Steatotic Liver Disease. Digestive Diseases and Sciences. 2025. doi:10.1007/s10620-024-08724-y
BibTeX
@article{Bollinger2025,
author = {Bollinger, Bryan and Cotter, Robert and Deng, Yanhong and Ilagan-Ying, Ysabel and Gupta, Vikas},
title = {Presence of Mood and/or Anxiety Disorders Does Not Affect Success of Weight Management Therapies in Metabolic Dysfunction-Associated Steatotic Liver Disease},
journal = {Digestive Diseases and Sciences},
year = {2025},
doi = {10.1007/s10620-024-08724-y}
}
EUVIMED